AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks

NORTH CHICAGO, Ill., June 12, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior rates of skin clearance for SKYRIZI (risankizumab-rzaa)A to COSENTYX (secukinumab) at week 52.1 Particularly, 66 percent of psoriasis patients receiving SKYRIZIA achieved completely clear skina??100 percent clearance in the Psoriasis Area and Severity Index (PASI 100)a??versus 40 percent of patients receiving COSENTYX at week 52 (p<0.001).1These new head-to-head results from the IMMerge Phase 3b open-label study were shared today during an online late-breaking presentation by the American Academy of Dermatology (AAD). AbbVie previously announcedA top-line results from this study in January."I've seen first-hand how achieving and maintaining completely clear skin can have an incredibly positive impact on the lives of my psoriasis patients," said chief investigator Richard B. Warren, M.D., Ph.D., professor and honorary consultant dermatologist at the Dermatology Centre Salford Royal NHS Foundation Trust, University of Manchester. "These new data are critical as they underscore that complete skin clearance is a realistic treatment goal for people living with psoriasis."SKYRIZI met both PASI 90 primary endpoints of non-inferiority to COSENTYX at week 16 and superiority to COSENTYX at week 52.1 At week 16, 74 percent of SKYRIZI-treated patients achieved PASI 90 compared to 66 percent of COSENTYX-treated patients.1 Of patients treated with SKYRIZI, 87 percent achieved PASI 90 at week 52 compared to 57 percent of patients treated with COSENTYX (p<0.001).1Additional results demonstrated a significantly higher proportion of patients treated with SKYRIZI achieved a static Physician Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1) compared to those treated with COSENTYX at week 52 (88 percent versus 58 percent, respectively, p<0.001).1
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2021    »